Skip to main content

Research Repository

Advanced Search

Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)

Hickman, Matthew; Dillon, John F; Elliott, Lawrie; De Angelis, Daniela; Vickerman, Peter; Foster, Graham; Donnan, Peter; Eriksen, Ann; Flowers, Paul; Goldberg, David; Hollingworth, William; Ijaz, Samreen; Liddell, David; Mandal, Sema; Martin, Natasha; Beer, Lewis J Z; Drysdale, Kate; Fraser, Hannah; Glass, Rachel; Graham, Lesley; Gunson, Rory N; Hamilton, Emma; Harris, Helen; Harris, Magdalena; Harris, Ross; Heinsbroek, Ellen; Hope, Vivian; Horwood, Jeremy; Inglis, Sarah Karen; Innes, Hamish; Lane, Athene; Meadows, Jade; McAuley, Andrew; Metcalfe, Chris; Migchelsen, Stephanie; Murray, Alex; Myring, Gareth; Palmateer, Norah E; Presanis, Anne; Radley, Andrew; Ramsay, Mary; Samartsidis, Pantelis; Simmons, Ruth; Sinka, Katy; Vojt, Gabriele; Ward, Zoe; Whiteley, David; Yeung, Alan; Hutchinson, Sharon J


Matthew Hickman

John F Dillon

Lawrie Elliott

Daniela De Angelis

Peter Vickerman

Graham Foster

Peter Donnan

Ann Eriksen

Paul Flowers

David Goldberg

William Hollingworth

Samreen Ijaz

David Liddell

Sema Mandal

Natasha Martin

Lewis J Z Beer

Kate Drysdale

Hannah Fraser

Rachel Glass

Lesley Graham

Rory N Gunson

Emma Hamilton

Helen Harris

Magdalena Harris

Ross Harris

Ellen Heinsbroek

Vivian Hope

Jeremy Horwood

Sarah Karen Inglis

Hamish Innes

Athene Lane

Jade Meadows

Andrew McAuley

Chris Metcalfe

Stephanie Migchelsen

Alex Murray

Gareth Myring

Norah E Palmateer

Anne Presanis

Andrew Radley

Mary Ramsay

Pantelis Samartsidis

Ruth Simmons

Katy Sinka

Gabriele Vojt

Zoe Ward

David Whiteley

Alan Yeung

Sharon J Hutchinson


Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV prevalence remains around 40% among people who inject drugs (PWID). New direct-acting antiviral (DAA) HCV therapies comine high cure rates (>90%) and short treatment duration (8 to 12 weeks). Theoretical mathematical modelling evidence suggests HCV treatment scale-up can prevent transmission and substantially reduce HCV prevalence/incidence among PWID. Our primary aim is to generate empirical evidence on the effectiveness of HCV ‘Treatment as Prevention’ (TasP) in PWID.

Journal Article Type Article
Acceptance Date Jul 29, 2019
Online Publication Date Sep 24, 2019
Publication Date 2019-09
Deposit Date Sep 25, 2019
Publicly Available Date Sep 25, 2019
Journal BMJ Open
Electronic ISSN 2044-6055
Publisher BMJ Publishing Group
Peer Reviewed Peer Reviewed
Volume 9
Issue 9
Article Number e029538
Public URL


Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) (1.9 Mb)

Publisher Licence URL

Copyright Statement
This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: 0/.

You might also like

Downloadable Citations